Co-Diagnostics, Inc. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Co-Diagnostics Inc. issued a Senior Secured Convertible Note to J.J. Astor Co. (a Utah corporation) on November 18, 2026. Net funding: $960,000 (after $40,000 origination fee); original principal amount: $1,350,000 (including $350,000 original issue discount). Repayment: 30 weekly installments of $45,000 each through June 16, 2027. The note is convertible into common stock at a floor price of 20% of the Nasdaq Minimum Price, subject to a 9.99% (expandable to 19.99%) beneficial ownership cap. Repayment can be satisfied via ATM equity sales proceeds or conversion into registered shares.
Why this rating
Debt issuance of $960K net (9.6% of $10M market cap) with aggressive terms: 20% floor conversion price, 19% default interest, 120% default multiplier, mandatory equity waterfall, and two-week cure periods. Dilutive equity conversion and near-term repayment pressure pose material refinancing and shareholder value risk for micro-cap company.
Price action (we called it negative)
before filing · preread $0.13 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.